Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Abstract
nevertheless, in contrast to cancer of the breast, other HER2-targeted methods of date never have improved outcomes in this molecular subtype of GEA. Since the development that is initial of biomarker evaluating instructions, significant spatial intratumoral heterogeneity of HER2 overexpression was recognized as a major characteristic of this infection. In this review, we try to review the seminal positive and negative trials investigating HER2-targeted agents for GEA. Continue reading “HER2 phrase remains a biomarker that is important guide the addition associated with monoclonal antibody trastuzumab to first-line systemic chemotherapy in unresectable, metastatic gastroesophageal adenocarcinomas (GEA).”